Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Biotech Milestones to Watch in Q3: Obesity Drugs, Genetic Testing and More
Biotech Milestones to Watch in Q3: Obesity Drugs, Genetic Testing and More
Biotech Milestones to Watch in Q3: Obesity Drugs, Genetic Testing and More
Submitted by
admin
on July 7, 2010 - 9:36am
Source:
BNET Pharma
News Tags:
Vivus
Qnexa
Myriad
Genomic Health
NicOx
naproxcinod
Savient
Krystexxa
Novartis
Gilenia
Seattle Genetics
Gilead Sciences
Chelsea Therapeutics
Eisai
Headline:
Biotech Milestones to Watch in Q3: Obesity Drugs, Genetic Testing and More
Do Not Allow Advertisers to Use My Personal information
